Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J7170 Injection., emicizumab-kxwh 0.5 milligrams

J Codes (Drugs)

Also known as: emicizumab, Hemlibra, bridging antibody

Injection of emicizumab-kxwh, a bispecific monoclonal antibody that bridges Factor Xa and Factor IXa in the coagulation cascade, supplied as 0.5 milligrams per dose.

In Plain Language

clotting factor replacement therapy; hemophilia A treatment

Clinical Context

Indicated for prophylaxis of breakthrough bleeding in hemophilia A patients with Factor VIII inhibitors (inhibitor patients), administered as prophylactic therapy to prevent bleeding episodes.

RVU Information

CPT J7170 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

HematologyHemophilia Specialty ClinicInternal Medicine

Frequently Asked Questions

What is CPT code J7170?

CPT J7170 (Injection., emicizumab-kxwh 0.5 milligrams) is a J Codes (Drugs) code. Injection of emicizumab-kxwh, a bispecific monoclonal antibody that bridges Factor Xa and Factor IXa in the coagulation cascade, supplied as 0.5 milligrams per dose.

How is J7170 administered?

CPT J7170 is administered by a healthcare provider, typically via injection or infusion. Indicated for prophylaxis of breakthrough bleeding in hemophilia A patients with Factor VIII inhibitors (inhibitor patients), administered as prophylactic therapy to prevent bleeding episodes. It is used by Hematology, Hemophilia Specialty Clinic, Internal Medicine.

When is CPT J7170 used?

Indicated for prophylaxis of breakthrough bleeding in hemophilia A patients with Factor VIII inhibitors (inhibitor patients), administered as prophylactic therapy to prevent bleeding episodes.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.